PE anti-human CD3 Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation, and activation of T lymphocytes^4-7. The HIT3a antibody is able to stimulate T cell activation. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300314). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 300332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Sedelies KA, et al. 2004. J. Biol. Chem. 279:26581. (Activ)
5. Rivollier A, et al. 2004. Blood 104:4029. (Activ)
6. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Activ)
7. Smeltz RB. 2007. J. Immunol. 178:4786. (Activ)

Product Citations

1. Wu Y, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed
2. Kwee BJ, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
3. Li Y, et al. 2022. J Med Virol. 94:3998. PubMed
4. Busek M, et al. 2023. Lab Chip. 23:591. PubMed
5. Pan R, et al. 2022. Cell. 185:1521. PubMed
6. Im NG, et al. 2022. Cancer Immunol Res. 10:1055. PubMed
7. Yang Y, et al. 2023. Front Immunol. 14:1033497. PubMed
8. Wang H, et al. 2020. J Exp Clin Cancer Res. 39:29. PubMed
9. Lin GL, et al. 2018. Acta Neuropathol Commun. 9:617. PubMed
10. Galindo-Albarrán A, et al. 2016. Cell Rep. 17:2151-2160. PubMed
11. Rochat MA, et al. 2018. Virol J. 15:191. PubMed
12. Bardet M, et al. 2018. Immunol Cell Biol. 96:81. PubMed
13. Kokkinopoulos I, et al. 2021. Sci Rep. 11:15759. PubMed
14. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
15. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
16. Enghard P, et al. 2014. Ann Rheum Dis. 73:277. PubMed
17. Liu F, et al. 2020. Oncoimmunology. 9:1746573. PubMed
18. González-Jiménez A, et al. 2022. Int J Mol Sci. 23: . PubMed
19. Park JA, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
20. Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed
21. Blandine Monel et al. 2019. Cell reports. 27(1):142-153 . PubMed
22. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
23. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
24. Pellegrini JM, et al. 2021. Sci Rep. 11:13559. PubMed
25. Pereira PMR, et al. 2022. Nat Commun. 13:2526. PubMed
26. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
27. Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed
28. Liu J, et al. 2021. Medicine (Baltimore). 100:e24619. PubMed
29. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
30. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
31. Platten M, et al. 2021. Nature. 592:463. PubMed
32. Valestrand L, et al. 2022. Am J Pathol. . PubMed
33. Mori A, et al. 2021. Cells. :10. PubMed
34. Joly P, et al. 2017. PLoS One. 12(6):e0180568. PubMed
35. Usmani SM et al. 2019. Cell host & microbe. 25(1):73-86 . PubMed
36. Cheng J, et al. 2021. Biomed Res Int. 2021:6614784. PubMed
37. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
38. Park JA, et al. 2020. J Hematol Oncol. 0.661111111. PubMed
39. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
40. Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed
41. Łyszkiewicz M, et al. 2020. Nat Commun. 11:1031. PubMed
42. Wang X, et al. 2022. J Exp Clin Cancer Res. 41:210. PubMed
43. Pekayvaz K, et al. 2022. Nat Commun. 13:1018. PubMed
44. Ma S, et al. 2022. Nat Commun. 13:4118. PubMed
45. Hu JQ, et al. 2020. J Cancer. 3.409722222. PubMed
46. Zhai Y, et al. 2018. Autophagy. 1.714583333. PubMed

RRID

AB_314043 (BioLegend Cat. No. 300307)
AB_314043 (BioLegend Cat. No. 300308)

Antigen Details

Structure

Ig superfamily, with the subunits of CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD

Distribution

Mature T and NK-T cells, thymocyte differentiation

Function

Antigen recognition, signal transduction, T cell activation

Ligand/Receptor

Peptide antigen bound to MHC

Cell Type

NKT cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules, TCRs

Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.

Gene ID

916 View all products for this Gene ID

UniProt

View information about CD3 on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats